Page de couverture de From Brazil to the US: Unpacking ANVISA and FDA 510(k) Pathways

From Brazil to the US: Unpacking ANVISA and FDA 510(k) Pathways

From Brazil to the US: Unpacking ANVISA and FDA 510(k) Pathways

Écouter gratuitement

Voir les détails du balado

À propos de cet audio

 This episode tackles a common question from MedTech manufacturers: can a successful ANVISA registration in Brazil streamline the path to FDA 510(k) clearance in the United States? We explore the reality of regulatory reliance between these two key markets, clarifying the one-way nature of current frameworks and outlining how your existing ANVISA technical documentation can still provide a significant advantage for your US submission. • Does the FDA recognize or have a reliance pathway for ANVISA-approved medical devices? • What is Brazil's new "Reliance" program (IN 290/2024) and how does it affect US manufacturers? • Can the technical dossier created for ANVISA be used for an FDA 510(k) submission? • What are the fundamental differences between an ANVISA registration and an FDA 510(k)? • How does the concept of a "predicate device" make the 510(k) process unique? • Can my BGMP (Brazilian Good Manufacturing Practices) certification help with FDA QSR compliance? • What parts of my ANVISA submission, like clinical data and risk analysis, can be repurposed? • What are the critical gaps I need to fill when moving from a Brazilian approval to a US submission? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email info@pureglobal.com for tailored support.
Pas encore de commentaire